靶向表皮生长因子受体的新型 1,3,4-噁二唑萘普生衍生物:合成、分子对接研究和细胞毒性评估。

IF 3.5 4区 医学 Q2 CHEMISTRY, MEDICINAL Drug Development Research Pub Date : 2024-07-02 DOI:10.1002/ddr.22231
Hiba N. Alsaad, Baan M. AL-Jasani, Ammar A. Razzak Mahmood, Lubna H. Tahtamouni, Khaled M. Saleh, Mai F. AlSakhen, Sana I. Kanaan, Salem R. Yasin
{"title":"靶向表皮生长因子受体的新型 1,3,4-噁二唑萘普生衍生物:合成、分子对接研究和细胞毒性评估。","authors":"Hiba N. Alsaad,&nbsp;Baan M. AL-Jasani,&nbsp;Ammar A. Razzak Mahmood,&nbsp;Lubna H. Tahtamouni,&nbsp;Khaled M. Saleh,&nbsp;Mai F. AlSakhen,&nbsp;Sana I. Kanaan,&nbsp;Salem R. Yasin","doi":"10.1002/ddr.22231","DOIUrl":null,"url":null,"abstract":"<p>The close association between inflammation and cancer inspired the synthesis of a series of 1,3,4-oxadiazole derivatives (compounds <b>H4-A-F</b>) of 6-methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier-transform infrared, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer-aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription-polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds <b>H4-A</b>, <b>H4-B</b>, <b>H4-C</b>, and <b>H4-E</b> show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds <b>H4-A</b>, <b>H4-C</b>, and <b>H4-F</b> are nontoxic. Compound <b>H4-A</b> showed the best-fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound <b>H4-C</b> was the most cytotoxic. Compound <b>H4-C</b> caused cytotoxicity in HCT-116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds <b>H4-D, H4-C</b>, and <b>H4-B</b> had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.</p>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"85 5","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation\",\"authors\":\"Hiba N. Alsaad,&nbsp;Baan M. AL-Jasani,&nbsp;Ammar A. Razzak Mahmood,&nbsp;Lubna H. Tahtamouni,&nbsp;Khaled M. Saleh,&nbsp;Mai F. AlSakhen,&nbsp;Sana I. Kanaan,&nbsp;Salem R. Yasin\",\"doi\":\"10.1002/ddr.22231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The close association between inflammation and cancer inspired the synthesis of a series of 1,3,4-oxadiazole derivatives (compounds <b>H4-A-F</b>) of 6-methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier-transform infrared, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer-aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription-polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds <b>H4-A</b>, <b>H4-B</b>, <b>H4-C</b>, and <b>H4-E</b> show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds <b>H4-A</b>, <b>H4-C</b>, and <b>H4-F</b> are nontoxic. Compound <b>H4-A</b> showed the best-fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound <b>H4-C</b> was the most cytotoxic. Compound <b>H4-C</b> caused cytotoxicity in HCT-116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds <b>H4-D, H4-C</b>, and <b>H4-B</b> had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.</p>\",\"PeriodicalId\":11291,\"journal\":{\"name\":\"Drug Development Research\",\"volume\":\"85 5\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Development Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22231\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

炎症与癌症之间的密切联系启发了我们合成一系列 6-甲氧基萘的 1,3,4-恶二唑衍生物(化合物 H4-A-F)。利用傅立叶变换红外光谱、质子核磁共振、碳-13 核磁共振光谱技术和 CHN 分析验证了新化合物的化学结构。利用计算机辅助药物设计方法预测了化合物的生物靶点、ADMET 特性、毒性,并评估了设计化合物与标准表皮生长因子受体(EGFR)抑制剂厄洛替尼之间的分子相似性。新化合物的抗增殖作用通过 3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2H-四氮唑溴化物试验、细胞周期分析、显微镜凋亡检测、定量反转录聚合酶链反应和免疫印迹法以及表皮生长因子受体酶抑制试验进行了评估。对新型噁二唑衍生物的硅学分析表明,这些化合物以表皮生长因子受体为靶点,化合物 H4-A、H4-B、H4-C 和 H4-E 显示出与厄洛替尼相似的分子特性。此外,研究结果表明,合成的化合物均不致癌,化合物 H4-A、H4-C 和 H4-F 无毒。化合物 H4-A 与表皮生长因子受体药代动力学模型的拟合得分最高,但体外研究表明化合物 H4-C 的细胞毒性最强。化合物 H4-C 通过诱导细胞凋亡和坏死,对 HCT-116 大肠癌细胞产生细胞毒性。此外,化合物H4-D、H4-C和H4-B对表皮生长因子受体酪氨酸激酶的抑制作用与厄洛替尼相当。这一研究结果为进一步研究合成化合物与厄洛替尼之间的差异提供了基础。不过,要评估所有这些差异并确定最有希望进一步研究的化合物,还需要进行更多的测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation

The close association between inflammation and cancer inspired the synthesis of a series of 1,3,4-oxadiazole derivatives (compounds H4-A-F) of 6-methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier-transform infrared, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer-aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription-polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds H4-A, H4-B, H4-C, and H4-E show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds H4-A, H4-C, and H4-F are nontoxic. Compound H4-A showed the best-fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound H4-C was the most cytotoxic. Compound H4-C caused cytotoxicity in HCT-116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds H4-D, H4-C, and H4-B had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.40
自引率
2.60%
发文量
104
审稿时长
6-12 weeks
期刊介绍: Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.
期刊最新文献
New Dichalcogenides Induce Oxidative Stress and Cell Death of Leishmania amazonensis Unveiling Immunotherapy Evasion in Lung Cancer: The Role of Fanconi Anemia and Stemness Genes in Shaping an Immunosuppressive Microenvironment Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia Issue Information Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposomal Formulation for Managing Breast Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1